Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor

Children's Oncology Group20 enrolled

Overview

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood and tumor tissue samples from patients with Wilms tumor.

OBJECTIVES: * To determine whether Wilms Tumor (WT) patients without WT1-associated congenital anomalies or syndromes, but with end-stage renal disease (ESRD) unrelated to progressive bilateral tumors, carry germline WT1 mutations. * To determine whether non-syndromic WT1 germline mutation carriers have a substantially higher incidence of ESRD than do WT patients who do not harbor WT1 mutations. OUTLINE: Archived blood and tumor tissue specimens (or DNA isolated from these samples) are analyzed for WT1 mutations by gene sequencing and PCR.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Kidney Cancer Renal Failure

Interventions

mutation analysisGENETIC

polymerase chain reactionGENETIC

laboratory biomarker analysisOTHER

Eligibility

Sex: ALLMax age: 15 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of Wilms Tumor (WT) * Patients who participated in the NWTS-5 protocol * Non-syndromic patients who developed end-stage renal disease (ESRD) during 5-10 years for reasons other than progressive bilateral WT * Matched control patients who had not developed ESRD by the time (since WT onset) of ESRD diagnosis * Blood and tumor tissue samples available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Outcomes

Primary Outcomes

Higher incidence of ESRD in non-syndromic WT patients with germline WT1 mutations than WT patients without WT1 mutations

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.